1-2 of 2
Clarisse Dromain
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study

Angela Lamarca, Maxime Ronot, Salma Moalla, Joakim Crona, Marta Opalinska, Carlos Lopez Lopez, Daniela Pezzutti, Pavan Najran, Luciana Carvhalo, Regis Otaviano Franca Bezerra, Philip Borg, Naik Vietti Violi, Hector Vidal Trueba, Louis de Mestier, Niklaus Scaefer, Eric Baudin, Anders Sundin, Frederico Costa, Marianne Pavel, Clarisse Dromain
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6692–6699.
https://doi.org/10.1158/1078-0432.CCR-19-0963
Published: 15 November 2019
View article titled, Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study
Open the PDF for Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study in another window
Includes: Supplementary data
Journal Articles

Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials

Charles Ferté, Marianna Fernandez, Antoine Hollebecque, Serge Koscielny, Antonin Levy, Christophe Massard, Rastislav Balheda, Brian Bot, Carlos Gomez-Roca, Clarisse Dromain, Samy Ammari, Jean-Charles Soria
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (1): 246–252.
https://doi.org/10.1158/1078-0432.CCR-13-2098
Published: 05 January 2014
View article titled, Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials
Open the PDF for Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials in another window
Includes: Supplementary data